Nantes, France, March 10, 2026 - 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the transition of Marc Le Bozec from interim to permanent Chief Executive Officer, effective immediately. Mr. Le Bozec had served as interim CEO since October 2, 2025.
Following a thorough review of internal and external candidates and upon recommendation of the Nomination and Compensation Committee, the Board of Directors unanimously confirmed Marc Le Bozec's transition from interim to permanent CEO.
Dr. Markus Cappel, Chairman of the Board of OSE Immunotherapeutics, commented:
"I am thrilled to announce Marc's permanent appointment as CEO. Since stepping into the interim role, Marc has demonstrated the strategic 'grit' and visionary leadership required to navigate the complexities of our sector. His deep understanding of our pipeline and his ability to unite the team behind a common mission have been exemplary. The Board is fully aligned with Marc's vision to scale our current assets into commercial successes, and we are confident that his leadership will drive significant value for our shareholders and, most importantly, for the patients who depend on our innovation."
Marc Le Bozec, Chief Executive Officer of OSE Immunotherapeutics, added:
"I am deeply honored and energized to lead OSE Immunotherapeutics at such a pivotal moment in our journey. We are at a transition point where our scientific excellence is meeting critical clinical and commercial milestones. My focus is clear: to accelerate our breakthrough therapies and ensure that our novel medicines reach the patients in need as quickly as possible. OSE possesses a world-class R&D engine and a pipeline with transformative potential, and I am eager to work alongside Markus, the Board and our talented team to unlock the full value of these assets."
A Renewed Commitment to Patients
This appointment reinforces OSE's core mission of bringing life-changing treatments to patients facing high unmet medical needs. The Company remains steadfast in its goal to deliver novel immunotherapies in the fields of immuno-oncology and immuno-inflammation, with a focus on precision medicine and patient-centric clinical development.
The compensation policy of Mr. Le Bozec for his position as Chief Executive Officer, as determined by the Board of Directors on the recommendation of the Nomination and Compensation Committee, will be published in the Company's 2025 Universal Registration Document and submitted to the vote of the Company's Annual Shareholders' Meeting, which will be called upon to approve the financial statements for the fiscal year ending December 31, 2025.
ABOUT OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is listed on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: www.ose-immuno.com. Follow us on LinkedIn
Contacts
OSE Immunotherapeutics: investors@ose-immuno.com
FP2COM: Florence Portejoie: fportejoie@fp2com.fr I +33 6 07 768 283
Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.
These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.
